CORCEPT THERAPEUTICS INC (CORT) Analyst Ratings
CORT Analyst Consensus & Price Target
CORCEPT THERAPEUTICS INC (CORT) carries a consensus rating of Moderate Buy from 6 analysts on record (Aug 1, 2022 to Aug 18, 2026): 3 bullish, 2 neutral, 1 bearish. The average price target is $60.00 (range $22.00 to $164.00), with wide disagreement among analysts. That implies +47.3% downside from the current price of $113.88. Recent activity leans toward downgrades: 3 upgrades vs 4 downgrades on record. The price target on record has moved from $30.00 to $164.00 (+446.7%) between Aug 1, 2022 and Aug 18, 2026.
One vote per analyst, using each firm's most recent rating on record, not every historical reiteration counted separately.
Each analyst's most recent target on record, compared against where the stock actually trades. See how actual results have compared to estimates →
Is the average price target keeping pace with the stock, running ahead of it, or lagging behind? Compares the target's overall drift on record (across different analysts) to the stock's own move over the same window.
Price targets have risen faster than the stock itself.
Every rating on record, most recent first. "Next-close move" is the stock's own move from the prior close to the rating date's close, where price history lines up, a data point per event, not an averaged claim.
| Date | Analyst | Action | Rating | Price Target | Move |
|---|---|---|---|---|---|
| Aug 18, 2026 | Truist | Resumed | Buy | $164 | — |
| Jul 27, 2026 | Wolfe Research | Downgrade | Peer Perform to Underperform | $50 | -4.45% |
| May 13, 2026 | UBS | Upgrade | Neutral to Buy | $72 | +11.57% |
| Mar 26, 2026 | Wolfe Research | Upgrade | Underperform to Peer Perform | — | -4.79% |
| Dec 31, 2025 | Wolfe Research | Downgrade | Peer Perform to Underperform | $30 | -50.43% |
| Dec 16, 2025 | UBS | Initiated | Neutral | — | -7.08% |
| Nov 18, 2025 | Wolfe Research | Initiated | Peer Perform | — | -0.01% |
| Nov 6, 2023 | Truist | Upgrade | Hold to Buy | $29 to $38 | +1.13% |
| Apr 11, 2023 | SVB Securities | Initiated | Market Perform | $25 | -2.52% |
| Apr 4, 2023 | Piper Sandler | Initiated | Overweight | $27 | -2.18% |
| Feb 15, 2023 | Jefferies | Downgrade | Buy to Hold | $35 to $22 | -4.46% |
| Aug 1, 2022 | Truist | Downgrade | Buy to Hold | $30 | -4.64% |
What is the analyst consensus rating for CORT?
CORCEPT THERAPEUTICS INC's consensus rating is Moderate Buy, based on 6 analysts' most recent ratings on record: 3 bullish, 2 neutral, 1 bearish.
What is CORT's average analyst price target?
The average price target on record is $60.00, ranging from $22.00 to $164.00 across 6 analysts, wide disagreement. That implies -47.3% from the current price of $113.88.
Are analysts upgrading or downgrading CORT right now?
On record between Aug 1, 2022 and Aug 18, 2026: 3 upgrades, 4 downgrades, 4 new initiations, and 0 reiterations.
Are analyst price targets for CORT rising or falling?
The price target on record moved from $30.00 on Aug 1, 2022 to $164.00 on Aug 18, 2026, a change of +446.7%. This compares different analysts over time, not one analyst's revision.
How many analysts cover CORT?
6 analysts have rated CORT in the data on record, spanning Aug 1, 2022 to Aug 18, 2026.